What is the difference between the Indian version of Venetocla/Venetocla and the original version?
Venetoclax/Venetoclax is a new oral small molecule drug targeting BCL-2. It is mainly used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). Venetoclax is a BH3 analogue. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, causing programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies is associated with increased chemoresistance.

In terms of the source of the drug, the original version of Venetoclax was jointly developed by AbbVie (Albertville) and Genentech and is an original drug. The Indian version of Venekra is a generic drug, produced by Indian pharmaceutical companies based on the ingredients and manufacturing process of the original drug. It should be noted that India does not produce the original drug or generic version of Venacla. Common generic drug manufacturers are Bangladesh and Laos versions,
In terms of drug quality and efficacy, the generic version of Venetoclax is highly similar to the original drug. Generic version pharmaceutical companies will strictly follow international drug production standards and quality control processes during the imitation process to ensure that the dosage, safety and efficacy of the generic drugs are consistent with the original drugs. Therefore, the generic version of venetoclax is equivalent to the original drug in terms of therapeutic efficacy and safety.
In terms of price, the generic version of venetoclax has significant advantages, but patients still need to be cautious when purchasing. It is important to ensure that you purchase generic drugs that have gone through formal channels and have guaranteed quality. In comparison, the original version of Venekra is relatively expensive due to factors such as research and development costs and patent protection. At the same time, before using any medicine, you should consult a doctor or pharmacist for advice to ensure the rationality and safety of the medication.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)